- Research article
- Open Access
- Open Peer Review
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
© Raponi et al; licensee BioMed Central Ltd. 2004
- Received: 30 April 2004
- Accepted: 25 August 2004
- Published: 25 August 2004
Farnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that there are several other potential targets for this drug class. The FTI tipifarnib (ZARNESTRA™, R115777) has recently demonstrated clinical responses in adults with refractory and relapsed acute leukemias. This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML).
Tipifarnib-mediated gene expression changes in 3 AML cell lines and bone marrow samples from two patients with AML were analyzed on a cDNA microarray containing approximately 7000 human genes. Pathways associated with these expression changes were identified using the Ingenuity Pathway Analysis tool.
The expression analysis identified a common set of genes that were regulated by tipifarnib in three leukemic cell lines and in leukemic blast cells isolated from two patients who had been treated with tipifarnib. Association of modulated genes with biological functional groups identified several pathways affected by tipifarnib including cell signaling, cytoskeletal organization, immunity, and apoptosis. Gene expression changes were verified in a subset of genes using real time RT-PCR. Additionally, regulation of apoptotic genes was found to correlate with increased Annexin V staining in the THP-1 cell line but not in the HL-60 cell line.
The genetic networks derived from these studies illuminate some of the biological pathways affected by FTI treatment while providing a proof of principle for identifying candidate genes that might be used as surrogate biomarkers of drug activity.
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Acute Myeloid Leukemia Cell
- Acute Myeloid Leukemia Cell Line
The investigative agent tipifarnib is a member of a new class of drugs that were designed to function as a non-peptidomimetic competitive farnesyltransferase inhibitor (FTI). The principal behind this drug class is that protein farnesylation is required for many cell-signaling processes and that dysregulation of cell signaling is thought to be instrumental in driving cell proliferation in several malignancies. The hypothesis that gave rise to this exciting class of drugs is that the inhibition of this enzyme would reduce the uncontrolled cell signaling and provide some control over cell division and malignant cell proliferation.
In hematological cancers, tipifarnib has shown significant inhibition of the proliferation of a variety of human tumor cell lines both in vitro and in vivo [1–3]. A recent phase I clinical trial of tipifarnib demonstrated a 32% response rate in patients with refractory or relapsed acute myeloid leukemia . Furthermore, tipifarnib activity has also been seen in early clinical trials for patients with myelodysplastic syndrome (MDS) [5, 6], multiple myeloma (MM) , and chronic myeloid leukemia (CML) .
Mechanism of action (MOA) and biomarker studies with tipifarnib have focused on the oncogenic Ras protein. However, it has since been shown that inhibition of Ras farnesylation does not account for all of the compound's actions. For example, FTIs do not require the presence of mutant Ras protein to produce anti-tumor effects . Several other proteins have been implicated as downstream targets that mediate the anti-tumorigenic effects of FTIs. The regulation of RhoB, a small GTPase that acts down-stream of Ras and is involved in many cellular processes including cytoskeletal regulation and apoptosis, has been proposed as a mechanism of FTI-mediated anti-tumorogenesis . Additional proteins involved in cytoskeletal organization are also known to be farnesylated including the centromere proteins, CENP-E and CENP-F, protein tyrosine phosphatase, and lamins A and B. Thus, one possible mode of action of FTI's may be due to their inhibiting effects on cellular reorganization and mitosis. In addition to possibly inhibiting cellular reorganization and mitotic pathways, it is also known that FTIs indirectly modulate several important signaling molecules including TGFβRII , MAPK/ERK , PI3K/AKT2 , Fas (CD95) and VEGF . The regulation of these effectors can lead to the modulation of signaling pathways involving cell growth and proliferation, and apoptosis. Thus, FTIs may have complex inhibitory effects on a number of cellular events.
Where there are multiple candidate pharmacologic biomarkers as is the case with tipifarnib, a comprehensive, parallel study of all candidates is required. Here we describe the application of DNA microarray technology to the measurement of the steady-state mRNA level of thousands of genes simultaneously. This comprehensive experimental approach allows for the simultaneous analysis of candidate biomarkers as well as the generation of novel hypothesis on MOA and previously uncharacterized biomarkers. Biomarkers that enable the monitoring of drug response have the potential to facilitate clinical evaluation of the compound's safety and efficacy in humans. In the present paper we describe the use of global gene expression monitoring to identify genes and gene pathways that are modulated in acute myeloid leukemia (AML) following treatment with tipifarnib. Several genes involved in FTI biology were identified as being modulated following treatment with tipifarnib in addition to pathways involved with cytoskeletal organization, cell signaling, immunity, and apoptosis. This genome-wide approach of gene expression analysis has provided insight into genes that can be used as surrogate biomarkers for FTI drug activity as well as identifying putative pathways that are involved in the drug's anti-leukemic mechanism of action. This is the first successful report of the application of genomics to this novel class of drugs.
The AML cell lines AML-193, HL-60, THP-1, and U-937 were obtained from the American Type Culture Collection (Manassas, VA). Cells were grown in RPMI supplemented with 20% FBS. AML-193 was also supplemented with GM-CSF (10 ng/ml; PeproTech Inc., Rocky Hill, NJ), insulin (0.005 mg/ml; Sigma-Aldrich, St. Louis, MO), and transferrin (0.005 mg/ml; Sigma-Aldrich, St. Louis, MO). Cell numbers were counted in a hemocytometer and cell viability was determined by trypan blue dye exclusion assay. Tipifarnib was dissolved in 0.1% DMSO. The IC50 was defined as the dose at which the number of viable cells in the treated sample was 50% of that in the control. This was determined after 7 days of drug treatment. Cytotoxicity assays were performed in duplicate. Control cultures were grown in medium containing vehicle (0.1% DMSO) only. Cells were analyzed for apoptosis by treating with vehicle or tipifarnib (100 nM and 1 μM) over a 5-day time course. Cells were stained with Annexin V and propidium iodide daily according to the manufacturers protocol (Roche Applied Science, Indianapolis, IN) and analyzed by FACS.
Bone marrow processing
Characteristics of patient AML samples.
M5, de novo AML
M4, de novo AML
Ras mutational status
Analysis of activating mutations in N-ras, K-ras, and H-ras codons was determined by PCR and RFLP analysis as previously described .
Total RNA was isolated using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and treated with DNase1 (DNase1 kit, Qiagen, Valencia, CA) to remove any residual genomic DNA. Probe preparation was performed as previously described . Linear amplification was performed on total RNA to obtain at least 15 μg of amplified RNA. Cell line mRNA and patient sample mRNA underwent one and two rounds of linear amplification respectively. Microarrays were generated and probes hybridized as described . Samples were hybridized to arrays that contained 7452 cDNAs from the IMAGE consortium (Integrated Molecular Analysis of Genome and their Expression: ResGen™, Invitrogen Life Technologies, Carlsbad, CA) and Incyte libraries (Incyte, Palo Alto, CA). The intensity level of each microarray was scaled so that the 75th percentile of the expression levels was equal across micro-arrays. To control for chip errors, replicate clones on each chip that displayed a coefficient of variance (CV) greater than 50% of the mean were excluded from the analysis. Since background intensity was a maximum of 30 relative fluorescent units (RFU) for all experiments, a threshold of 30 RFU was assigned to all clones exhibiting an expression level lower than this. The microarray data were then normalized by quantile normalization and logarithmically transformed before further analysis.
Analysis of variance (ANOVA) and t-tests were used to investigate the effect of drug treatment and time and their interactions for each gene. Multiple hypotheses testing was controlled by applying the false discovery rate (FDR) algorithm . All statistical analyses were performed in S-Plus 6.1 (Insightful Corporation). Ratio matrices were generated based on pair-wise analysis of treated versus control samples. Hierarchical clustering was performed using a correlation metric and complete linkage (OmniViz Pro™, OmniViz, Maynard, MA).
A total of 1198 genes that had a false discovery rate (FDR) < 0.1 (p < 0.05) in at least one cell line were used for the pathway analysis. Gene refseq accession numbers were imported into the Ingenuity Pathway Analysis software (Ingenuity Systems). 898 of these genes were mapped to the Ingenuity database. Seventy-two of these genes were also affected in patient samples (p < 0.05, FDR < 0.3) and were, therefore considered to be significantly regulated by tipifarnib. The identified genes were mapped to genetic networks available in the Ingenuity database and were then ranked by score. The score is the probability that a collection of genes equal to or greater than the number in a network could be achieved by chance alone. A score of 3 indicates that there is a 1/1000 chance that the focus genes are in a network due to random chance. Therefore, scores of 3 or higher have a 99.9% confidence of not being generated by random chance alone. This score was used as the cut-off for identifying gene networks significantly affected by tipifarnib.
Real Time RT-PCR
Primer sequences used for RT-PCR.
Response of AML-like cell lines to tipifarnib
Anti-proliferative effects of tipifarnib for AML cell lines.
K-ras(13) N-ras(12, 61)
Identification of genes differentially expressed in tipifarnib-treated AML cells
There are several known targets of FTIs including ras, RhoB, centromere proteins, lamins, PI3K/AKT, and TGFβRII [3, 10]. While the majority of these genes were present on our expression array (except the lamins) we only found k-ras to be significantly regulated. However, while not significant, up-regulation of TGFβRII was confirmed by RT-PCR (Fig 3). The absence of strong regulation of TGFβRII in the current data set may be due to the different FTI and/or the different culture conditions that were employed compared to previous reports . Interestingly, k-ras was significantly down-regulated in our system. While k-ras is a target of FTIs it has been shown to undergo alternative geranylgeranylation when farnesylation is inhibited and may therefore not be an important anti-tumorgenic target post-translationally; however, it maybe a relevant target at the transcriptional level . Repression of k-ras transcription has also been shown recently in a mouse model designed to identify genes that are related to the transformation-selective apoptotic program triggered by FTIs . K-ras may therefore warrant further investigation as a candidate transcriptional target of FTIs.
Identification of genetic networks affected by tipifarnib
To further refine the list of FTI-affected genes we next investigated which of these genes are known to interact biologically. To this end we carried out pathway analysis on the above 180 genes using the Ingenuity Pathway Analysis (IPA) tool. Seventy-nine (72 unique) of these 180 genes mapped to genetic networks as defined by the IPA tool. These networks describe functional relationships between gene products based on known interactions in the literature. The tool then associates these networks with known biological pathways. Five networks were found to be highly significant in that they had more of the identified genes present than would be expected by chance (Table 3). These networks were associated with the cell cycle, apoptosis, proliferation, chemotaxis, and immunity pathways. The study by Kamasani et al also found cell cycle pathways were repressed and immunity and cell adhesion pathways were activated by FTI treatment .
While the cell lines portrayed higher heterogeneity in expression changes compared with the patient samples, the hierarchical clustering did reveal a common set of up- and down-regulated genes. A set of 23 genes was found to be down-regulated in the cell line and patient samples (Fig. 4). The major network associated with these genes contained several involved in proliferation including CSK, FGFR3, KRAS2, PPARG, RET, and USF1. Alternatively, 29 genes were commonly up-regulated and network analysis of these revealed activation of apoptotic- and immune-related genes, including CASP6, CD48, FGR, IGF2R, PECAM1, and TNFRSF5. It will be of interest to investigate these genes further to see if they are transcriptional targets of FTIs and if their regulation is additive or synergistic to FTI efficacy.
Investigation of apoptosis
Tipifarnib is one of three FTIs that are currently in clinical trials for treating a variety of cancers  and it is showing promise in hematological malignancies [3–8]. While FTIs were originally designed to inhibit the function of the ras oncogene it has been recently demonstrated that there is no correlation between patient response and ras mutational status . Additionally, it is clear that other targets of FTIs exist that provide equally important anti-cancer properties. We have reported the use of microarray analysis of both primary human AML cells and AML cell lines following treatment with tipifarnib in order to identify genes and gene pathways that are modulated by this FTI. In particular, genes involved in signaling pathways, down-stream cytoskeletal pathways, and apoptotic events were described. Pharmacodynamic markers that are currently used in the clinic, such as lamin A and HDJ2 , are direct markers of farnesyltransferase inhibition while the majority of genes identified in this work are likely downstream transcriptional targets. Both of these current candidate markers were not present on our microarrays so we did not report on their expression changes. Further analysis will be required to elucidate whether the expression changes seen in our work are due to direct or indirect effects of FTIs. Also, while the currently used clinical biomarkers do not correlate with patient response to FTIs the genes identified here may be candidates for patient stratification . We are therefore in the process of examining bone marrow specimens from larger phase 2 clinical trials with the aim of validating the panel of pharmacodynamic gene expression markers we have identified here. Such pharmacogenomic analysis will be very important in further elucidating the action of FTIs while providing a platform for identifying patients who could potentially respond to tipifarnib therapy.
MR wrote the manuscript and performed experiments. RTB performed Ras analysis. DA helped conceive the experiments. JEK and JEL were principal investigators in the clinical trials from which samples were received. YW helped conceive the experiments. All authors read and approved the final manuscript.
Genetic networks affected by tipifarnib
Genes in Ingenuity network*
CD226, CD24, CD36, CD63, CEBPD, CRKL, CSF2RB, CSK, DF, DOK1, FACL2, FCAR, FCER1G, FGFR1, GAB2, GP6, GRIN1, ICAM1, ICAM2, ICAM3, INPP5D, INSR, ITGAL, ITGB2, LAT, LYN, MAD2L1, NEDD9, PECAM1, PPARG, PTK2B, SORBS1, STAT5B, SYK, UCP2
Immunity Inflammation Apoptosis Cell death Adhesion
ABCB1, ADORA3, APOC3, AR, BRCA1, C20ORF14, CAV1, CCNA1, CCNB1-RS1, CCND1, CDK2, CDKN2A, CDKN2D, CKS1B, CREM, E2F1, E2F4, ELA2, ESRRA, FGFR3, GNAQ, GNB1, GNG5, HDAC1, ICAM1, JUN, KLKB1, LAMP1, MKI67, PLCB2, PTPN2, PTPN9, RB1, RBBP2, TTK
Cell cycle Transcription Apoptosis
ABCB1B, ARL6IP, BAX, BCL2, CAPN1, CDC25C, CDKN1A, CEBPE, CREM, CSF2RA, CSF3R, CTCF, EMP1, F2, FACL3, GPI, LTB4R, MAPK14, MARK3, MEF2A, MYC, MYCN, PIM1, PPP1R15A, PTGS2, RPL21, RPL6, RPS12, RPS16, RPS5, SERPIND1, SLC19A1, SP1, TP53, USF1
Cell cycle Cell death Proliferation
ANXA1, ANXA2, APOH, BCR (BREAKPOINT CLUSTER REGION), CD22, CD48, DOK2, EIF3S2, EIF3S6, EIF3S7, EPHA4, ERBB3, FGR, FN1, FYN, GRB2, HCLS1, IGF2R, IL6R, IL6ST, KRAS2, LCK, LIF, LY6, PLAU, PLAUR, PLG, RET, S100A10, SHC1, SLC11A1, ST14, TNC, TRPV4, ZFP106
Chemotaxis Proliferation Apoptosis
ACT1, APLP2, BIRC4, CAMKL, CASP3, CASP6, CASP8, CASP9, CCL20, DRPLA, EGR1, EIF4B, FKBP5, HNF4A, IFI30, LMNB1, LYZ, NR0B2, NR3C1, NUMA1, PCYT1A, PLEC1, PRKCZ, RELA, RELB, RIPK2, RPS6KA1, TAX1BP1, TNFRSF25, TNFRSF5, TRAF1, TRAF3, TRAF5, VIM, WEE1
Apoptosis Cell death Proliferation
We gratefully acknowledge Christine Lloyd for performing real time RT-PCR assays, and Anton Bittner and the Johnson and Johnson Pharmaceutical Research and Development microarray department for assisting with microarray procedures.
- End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001, 61: 131-7.PubMedGoogle Scholar
- Cox AD, Der CJ: Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol. 2002, 2: 388-93. 10.1016/S1471-4892(02)00181-9.View ArticlePubMedGoogle Scholar
- Lancet JE, Karp JE: Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003, 102: 3880-9. 10.1182/blood-2003-02-0633.View ArticlePubMedGoogle Scholar
- Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001, 97: 3361-9. 10.1182/blood.V97.11.3361.View ArticlePubMedGoogle Scholar
- Kurzrock R, Cortes J, Kantarjian H: Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002, 39: 20-4. 10.1053/shem.2002.36925.View ArticlePubMedGoogle Scholar
- Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, et al: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004, 22: 1287-92. 10.1200/JCO.2004.08.082.View ArticlePubMedGoogle Scholar
- Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, et al: Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004, 103: 3271-7. 10.1182/blood-2003-08-2764.View ArticlePubMedGoogle Scholar
- Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, et al: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003, 101: 1692-7. 10.1182/blood-2002-07-1973.View ArticlePubMedGoogle Scholar
- Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998, 17: 1439-45. 10.1038/sj.onc.1202175.View ArticlePubMedGoogle Scholar
- Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM: Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene. 2000, 19: 5525-33. 10.1038/sj.onc.1203920.View ArticlePubMedGoogle Scholar
- Morgan MA, Dolp O, Reuter CW: Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001, 97: 1823-34. 10.1182/blood.V97.6.1823.View ArticlePubMedGoogle Scholar
- Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000, 20: 139-48.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang B, Prendergast GC, Fenton RG: Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 2002, 62: 450-8.PubMedGoogle Scholar
- Salunga RC, Guo H, Luo L, Bittner A, Joy KC, Chambers JR, Wan JS, Jackson MR, Erlander MG: Gene expression analysis via cDNA microarrays of laser capture microdissected cells from fixed tissue. In: DNA Microarrays. Edited by: Schema M. 1999, Oxford: Oxford University Press, 121-137.Google Scholar
- Simmen KA, Singh J, Luukkonen BG, Lopper M, Bittner A, Miller NE, Jackson MR, Compton T, Fruh K: Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci U S A. 2001, 98: 7140-5. 10.1073/pnas.121177598.View ArticlePubMedPubMed CentralGoogle Scholar
- Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal Royal Statistical Society. 1995, B57: 289-300.Google Scholar
- Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997, 272: 14459-64. 10.1074/jbc.272.22.14459.View ArticlePubMedGoogle Scholar
- Kamasani U, Liu AX, Prendergast GC: Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther. 2003, 2: 273-80.View ArticlePubMedGoogle Scholar
- Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Rapp MJ, Robillard N, Bataille R, Amiot M: Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002, 16: 1664-7. 10.1038/sj.leu.2402629.View ArticlePubMedGoogle Scholar
- Liesveld JL, Lancet JE, Rosell KE, Menon A, Lu C, McNair C, Abboud CN, Rosenblatt JD: Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia. 2003, 17: 1806-12. 10.1038/sj.leu.2403063.View ArticlePubMedGoogle Scholar
- Haluska P, Dy G, Adjei A: Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer. 2002, 38: 1685-10.1016/S0959-8049(02)00166-1.View ArticlePubMedGoogle Scholar
- Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH: Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000, 6: 2318-25.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/4/56/prepub
This article is published under license to BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.